Vor Bio expands RemeGen partnership to add autoimmune drug RC298
VOR•Vor Bio expanded its RemeGen partnership to license RC298 exclusively outside Greater China. The deal includes approximately $56 million upfront and up to $300 million in development milestones for RemeGen.
1. Deal terms and development
Vor Bio expanded its partnership with RemeGen to license RC298, a long-acting dual BAFF/APRIL inhibitor, exclusively outside Greater China. Upfront consideration totals approximately $56 million: $10 million in cash and pre-funded warrants for 2.3 million shares valued at approximately $46 million. RemeGen could receive up to $300 million in development milestones, including $20 million for initial clinical development and technology transfer milestones.
2. Development responsibilities
A Chinese regulatory filing is expected in the first half of 2027, and RemeGen will lead preclinical and Phase 1 development in China. After Phase 1, Vor will assume subsequent clinical development, regulatory activities and commercialization outside Greater China.
